In the recent years, immunotherapy has become a potential strategy against various types of cancers. In light of this trend, two important components of the immune response signaling pathways – PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1), are often mentioned. PD-1 is a cell membrane protein that has a role in limiting immune-induced tissue destruction at sites of active inflammation.
Bulletin
The US company Trovagene signs transactions to deliver blood test In Europe and Middle East
The company,Trovagene, based in San Diego, Calif., announced in mid-January that it has entered into contracts to distribute its Trovera tests with a number of partners in Europe and the Middle East. Including Bulgaria, where the contract partner is NM Genomix.
Osimertinib for EGFR T790M – Positive Lung Cancer
Advanced non-small cell lung cancer is a major goal for the development of target therapies. At the moment, several therapies have been approved or are in the clinical trials stage. The assessment of their potential benefits is based on the mutation status of genes such as EGFR, ALK, ROS1 and others.
Immuno – oncology
In the recent years, immunotherapy has become a potential strategy against various types of cancers. In light of this trend, two important components of the immune response signaling pathways – PD-1 (programmed cell death 1) and PD-L1 (programmed cell death ligand 1), are often mentioned. PD-1 is a cell membrane protein that has a role in limiting immune-induced tissue destruction at sites of active inflammation.
The US company Trovagene signs transactions to deliver blood test In Europe and Middle East
The company,Trovagene, based in San Diego, Calif., announced in mid-January that it has entered into contracts to distribute its Trovera tests with a number of partners in Europe and the Middle East. Including Bulgaria, where the contract partner is NM Genomix.
Osimertinib for EGFR T790M – Positive Lung Cancer
Advanced non-small cell lung cancer is a major goal for the development of target therapies. At the moment, several therapies have been approved or are in the clinical trials stage. The assessment of their potential benefits is based on the mutation status of genes such as EGFR, ALK, ROS1 and others.